• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Early initiation of rhythm-control for atrial fibrillation associated with lower risk of adverse cardiovascular outcomes

byJessie WillisandTeddy Guo
June 4, 2021
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Compared to patients only receiving rate-control treatment, those who received rhythm-control treatment within one year of diagnosis of atrial fibrillation had a lower risk of adverse cardiovascular outcomes.

2. This association was not seen if the treatment was initiated over one year after the diagnosis of atrial fibrillation.

Evidence Rating Level: 2 (Good)

Study Rundown: As the aging population grows, the prevalence of atrial fibrillation increases along with it. While rate-control therapy and anti-coagulation provide some benefit, these patients are still at high risk of stroke and sudden death due to heart failure, especially during the first year after diagnosis. In a recent randomized-control trial, rhythm-control therapy (antiarrhythmic drugs, cardioversion, and ablation) was shown to be associated with a lower risk of adverse cardiovascular events than usual care in early atrial fibrillation patients. In response, this Korean study investigated the effectiveness of rhythm-control therapy versus rate-control therapy, in the context of those recently diagnosed in the past year. Using data from the NHIS of Korea, eligible patients were sorted into early versus late atrial fibrillation treatment, based on timing of treatment initiation being less or more than a year since diagnosis. The primary composite outcomes were cardiovascular death and treatment safety. In conclusion, no difference was found in the primary outcome between rate and rhythm-control in those whose treatment was initiated over a year after first diagnosis. Conversely, those in the early treatment group were shown to have significantly lower risk of adverse cardiac events with rhythm-control therapy than rate-control therapy. No safety differences were found between the two treatment groups, regardless of the timing of treatment initiation. Strengths of this study include its use of large-scale data, encompassing 97% of the Korean population, increasing its external validity in a clinical setting. Despite this, data on other variables was unfortunately limited, such as severity of the condition, as well as physician reasoning for choosing rhythm-control over rate-control, which could be an entry point for bias. Nevertheless, this study added further support that early initiation of rhythm-control treatment could be of benefit to those with atrial fibrillation over rate-control therapy alone.

Click to read the study in the BMJ

Relevant Reading: Early rhythm-control therapy in patients with atrial fibrillation

In-Depth [retrospective cohort]: This study used similar inclusion criteria to the EAST-AFNET 4 randomized-control trial. Using the NHIS of Korea since July 2011, atrial fibrillation patients were included if they were older than 75, had a history of TIA or stroke or met two of the following minor conditions: female, age > 65, heart failure, hypertension, diabetes mellitus, previous MI, or CKD. 6,312 and 16,323 patients were in the late and early treatment groups, as defined by initiation of treatment after or less than a year since first diagnosis. The primary outcome was a composite of death from different cardiovascular causes. The safety outcome was a composite of death from any cause, hospital admission or prespecified complications of rhythm-control treatment. Follow-up was done until 31 December 2015 or until death. Deaths within 180 days since the first prescription were not included. Results showed significant difference in hazard ratios between rhythm-control (7.42) vs. rate-control (9.25) in the early treatment group (hazard ratio 0.81, 95% CI 0.71-0.93; p=0.002). This association was not significant in the late treatment group. No difference in safety outcomes between the two treatments in both the early and late groups.

RELATED REPORTS

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

#VisualAbstract: Addition of posterior wall isolation to pulmonary vein isolation did not increase resolution of atrial fibrillation

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ablationacute myocardial infarctionamiodaroneanti-arrhythmicatrial fibrillationischemic strokemyocardial infarctionrate controlrhythm controlstrokeTransient Ischemic Attack
Previous Post

#VisualAbstract Phase 2 trial shows umbralisib is safe and effective in patients with chronic lymphocytic leukemia who are intolerant to BTK or PI3Kδ inhibitor therapy

Next Post

2 Minute Medicine Rewind June 7, 2021

RelatedReports

Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Cardiology

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

January 31, 2023
β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

January 27, 2023
#VisualAbstract: Addition of posterior wall isolation to pulmonary vein isolation did not increase resolution of atrial fibrillation
StudyGraphics

#VisualAbstract: Addition of posterior wall isolation to pulmonary vein isolation did not increase resolution of atrial fibrillation

January 17, 2023
Patient Basics: Atrial Fibrillation
Cardiology

Adding posterior wall isolation to pulmonary vein isolation not beneficial in ablation for patients with persistent atrial fibrillation — the CAPLA trial

January 16, 2023
Next Post
Colchicine may lower the risk of cardiovascular events in patients with coronary disease

2 Minute Medicine Rewind June 7, 2021

Few older adolescents meet recommended levels of physical activity

The effects of dietary and lifestyle interventions among pregnant women with overweight or obesity on early childhood outcomes

Compliance-linked incentives increase infant immunizations rates in rural India

Randomized trial of plant-derived vaccine for COVID-19

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Factors associated with breastfeeding rates in Canada
  • Efanesoctocog alfa is efficacious in treating severe hemophilia A
  • Mavacamten associated with improvement in submaximal exertional tolerance: A secondary analysis of the EXPLORER-HCM randomized trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options